drugset / Trial / NCT01018238
An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)
RandomizedSingle-groupDouble-blindTreatment
Summary
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics and signs of bioactivity of increasing repeated doses of NNC 151-0000-0000 in subjects with Systemic Lupus Erythematosus (SLE).
Timeline
- Start
- 2009-11
- Primary completion
- 2009-11
- Completion
- 2009-11
Outcome
Outcome not reported
Stopped: “See detailed description”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NNC 0151-0000-0000 | Other / unclassified | 0.05 mg/kg | Subcutaneous |
| Subject | NNC 0151-0000-0000 | Other / unclassified | 0.3 mg/kg | Subcutaneous |